Details of the Drug

General Information of Drug (ID: DMD9WSC)

Drug Name

Memantine

Synonyms

Memantine ER; Namenda XR; Memantine (extended release); Memantine (extended release), Forest

Indication

Disease Entry	ICD 11	Status	REF
Alzheimer disease	8A20	Approved	[1], [2]

Drug Type

Small molecular drug

Structure

3D MOL

2D MOL

#Ro5 Violations (Lipinski): 0

Molecular Weight (mw)

179.3

Topological Polar Surface Area (xlogp)

3.3

Rotatable Bond Count (rotbonds)

Hydrogen Bond Donor Count (hbonddonor)

Hydrogen Bond Acceptor Count (hbondacc)

ADMET Property

Absorption Tmax: The time to maximum plasma concentration (Tmax) is 3-7 h [3]
BDDCS Class: Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 3: high solubility and low permeability [4]
Bioavailability: 99% of drug becomes completely available to its intended biological destination(s) [5]
Elimination: Approximately 48% of administered memantine is excreted unchanged in urine [6]
Half-life: The concentration or amount of drug in body reduced by one-half in 60 - 100 hours [3]
Metabolism: The drug is metabolized via the liver [3]
MRTD: The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 1.324 micromolar/kg/day [7]
Vd: The volume of distribution (Vd) of drug is 9-11 L/kg [6]

Chemical Identifiers

Formula: C12H21N
IUPAC Name: 3,5-dimethyladamantan-1-amine
Canonical SMILES: CC12CC3CC(C1)(CC(C3)(C2)N)C
InChI: InChI=1S/C12H21N/c1-10-3-9-4-11(2,6-10)8-12(13,5-9)7-10/h9H,3-8,13H2,1-2H3
InChIKey: BUGYDGFZZOZRHP-UHFFFAOYSA-N

Cross-matching ID

PubChem CID: 4054
ChEBI ID: CHEBI:64312
CAS Number: 19982-08-2
DrugBank ID: DB01043
TTD ID: D01JEU
VARIDT ID: DR00023
INTEDE ID: DR2292
ACDINA ID: D00395

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
N-methyl-D-aspartate receptor (NMDAR)	TT9IK2Z	NOUNIPROTAC	Modulator	[8], [9]

------------------------------------------------------------------------------------

Drug Transporter (DTP)

DTP Name	DTP ID	UniProt ID	MOA	REF
Organic cation transporter 2 (SLC22A2)	DT9IDPW	S22A2_HUMAN	Substrate	[10]

------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA)

MIA Detail

Jump to Detail Molecular Interaction Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Disease Different from Memantine (Comorbidity)

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Comorbidity	REF
Mepyramine	DMB4SFH	Moderate	Additive anticholinergic effects by the combination of Memantine and Mepyramine.	Allergic/hypersensitivity disorder [4A80-4A8Z]	[30]
Phenyltoloxamine	DMKAEQW	Moderate	Additive anticholinergic effects by the combination of Memantine and Phenyltoloxamine.	Allergic/hypersensitivity disorder [4A80-4A8Z]	[30]
Desipramine	DMT2FDC	Moderate	Additive anticholinergic effects by the combination of Memantine and Desipramine.	Attention deficit hyperactivity disorder [6A05]	[31]
Cariprazine	DMJYDVK	Moderate	Additive anticholinergic effects by the combination of Memantine and Cariprazine.	Bipolar disorder [6A60]	[31]
OPC-34712	DMHG57U	Moderate	Additive anticholinergic effects by the combination of Memantine and OPC-34712.	Depression [6A70-6A7Z]	[31]
Clomipramine	DMINRKW	Moderate	Additive anticholinergic effects by the combination of Memantine and Clomipramine.	Depression [6A70-6A7Z]	[31]
Doxepin	DMPI98T	Moderate	Additive anticholinergic effects by the combination of Memantine and Doxepin.	Depression [6A70-6A7Z]	[31]
Mepenzolate	DM8YU2F	Moderate	Additive anticholinergic effects by the combination of Memantine and Mepenzolate.	Digestive system disease [DE2Z]	[31]
Oxybutynine	DMJPBAX	Moderate	Additive anticholinergic effects by the combination of Memantine and Oxybutynine.	Discovery agent [N.A.]	[31]
Diphenhydramine	DMKQTBA	Moderate	Additive anticholinergic effects by the combination of Memantine and Diphenhydramine.	Episodic vestibular syndrome [AB31]	[31]
Solifenacin	DMG592Q	Moderate	Additive anticholinergic effects by the combination of Memantine and Solifenacin.	Functional bladder disorder [GC50]	[31]
Belladonna	DM2RBWK	Moderate	Additive anticholinergic effects by the combination of Memantine and Belladonna.	Infectious gastroenteritis/colitis [1A40]	[31]
ITI-007	DMUQ1DO	Moderate	Additive anticholinergic effects by the combination of Memantine and ITI-007.	Insomnia [7A00-7A0Z]	[31]
Phenindamine	DMDTC7R	Moderate	Additive anticholinergic effects by the combination of Memantine and Phenindamine.	Nasopharyngitis [CA00]	[31]
Promethazine	DM6I5GR	Moderate	Additive anticholinergic effects by the combination of Memantine and Promethazine.	Nausea/vomiting [MD90]	[31]
Cyclizine	DM9G7BS	Moderate	Additive anticholinergic effects by the combination of Memantine and Cyclizine.	Nausea/vomiting [MD90]	[31]
Flavoxate	DMKV4NL	Moderate	Additive anticholinergic effects by the combination of Memantine and Flavoxate.	Pain [MG30-MG3Z]	[31]
Pergolide	DM14MAE	Minor	Additive dopaminergic effects by the combination of Memantine and Pergolide.	Parkinsonism [8A00]	[32]
Opicapone	DM1BKA6	Minor	Additive dopaminergic effects by the combination of Memantine and Opicapone.	Parkinsonism [8A00]	[32]
Levodopa	DMN3E57	Minor	Additive dopaminergic effects by the combination of Memantine and Levodopa.	Parkinsonism [8A00]	[32]
Bromocriptine	DMVE3TK	Minor	Additive dopaminergic effects by the combination of Memantine and Bromocriptine.	Parkinsonism [8A00]	[32]
Orphenadrine	DMW542E	Moderate	Additive anticholinergic effects by the combination of Memantine and Orphenadrine.	Parkinsonism [8A00]	[31]
Methylscopolamine	DM5VWOB	Moderate	Additive anticholinergic effects by the combination of Memantine and Methylscopolamine.	Peptic ulcer [DA61]	[31]
Levomepromazine	DMIKFEL	Moderate	Additive anticholinergic effects by the combination of Memantine and Levomepromazine.	Psychotic disorder [6A20-6A25]	[31]
Neupro	DMHEAB1	Minor	Additive dopaminergic effects by the combination of Memantine and Neupro.	Restless legs syndrome [7A80]	[32]
Quetiapine	DM1N62C	Moderate	Additive anticholinergic effects by the combination of Memantine and Quetiapine.	Schizophrenia [6A20]	[31]
Aripiprazole	DM3NUMH	Moderate	Additive anticholinergic effects by the combination of Memantine and Aripiprazole.	Schizophrenia [6A20]	[31]
Iloperidone	DM6AUFY	Moderate	Additive anticholinergic effects by the combination of Memantine and Iloperidone.	Schizophrenia [6A20]	[31]
Paliperidone	DM7NPJS	Moderate	Additive anticholinergic effects by the combination of Memantine and Paliperidone.	Schizophrenia [6A20]	[31]
Molindone	DMAH70G	Moderate	Additive anticholinergic effects by the combination of Memantine and Molindone.	Schizophrenia [6A20]	[31]
Thiothixene	DMDINC4	Moderate	Additive anticholinergic effects by the combination of Memantine and Thiothixene.	Schizophrenia [6A20]	[31]
Asenapine	DMSQZE2	Moderate	Additive anticholinergic effects by the combination of Memantine and Asenapine.	Schizophrenia [6A20]	[31]
Pimozide	DMW83TP	Moderate	Additive anticholinergic effects by the combination of Memantine and Pimozide.	Schizophrenia [6A20]	[31]
Chlorpheniramine	DM5URA2	Moderate	Additive anticholinergic effects by the combination of Memantine and Chlorpheniramine.	Vasomotor/allergic rhinitis [CA08]	[31]
Trimeprazine	DMEMV9D	Moderate	Additive anticholinergic effects by the combination of Memantine and Trimeprazine.	Vasomotor/allergic rhinitis [CA08]	[30]
Acrivastine	DMTIGA0	Moderate	Additive anticholinergic effects by the combination of Memantine and Acrivastine.	Vasomotor/allergic rhinitis [CA08]	[31]
-----------


⏷ Show the Full List of 36 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG

DIG Name	DIG ID	PubChem CID	Functional Classification
FD&C blue no. 2	E00446	2723854	Colorant
Quinoline yellow WS	E00309	24671	Colorant
Sodium stearyl fumarate	E00545	23665634	lubricant
Sunset yellow FCF	E00255	17730	Colorant
Ammonia	E00007	222	Alkalizing agent
Beta-D-lactose	E00099	6134	Diluent; Dry powder inhaler carrier; Lyophilization aid
Brushite	E00392	104805	Diluent
Carmellose sodium	E00625	Not Available	Disintegrant
Crospovidone	E00626	Not Available	Disintegrant
Eisenoxyd	E00585	56841934	Colorant
Ferric hydroxide oxide yellow	E00539	23320441	Colorant
Ferrosoferric oxide	E00231	14789	Colorant
Hypromellose	E00634	Not Available	Coating agent
Lactose monohydrate	E00393	104938	Binding agent; Diluent; Dry powder inhaler carrier; Lyophilization aid
Magnesium stearate	E00208	11177	lubricant
Polyethylene glycol 400	E00653	Not Available	Coating agent; Diluent; Ointment base; Plasticizing agent; Solvent; Suppository base; lubricant
Polyethylene glycol 4000	E00654	Not Available	Coating agent; Diluent; Ointment base; Plasticizing agent; Solvent; Suppository base; lubricant
Polyethylene glycol 6000	E00655	Not Available	Coating agent; Diluent; Ointment base; Plasticizing agent; Solvent; Suppository base; lubricant
Polyvinyl alcohol	E00666	Not Available	Coating agent; Emulsion stabilizing agent; Film/Membrane-forming agent
Povidone	E00667	Not Available	Binding agent; Coating agent; Disintegrant; Film/membrane-forming agent; Solubilizing agent; Suspending agent
Saccharose	E00091	5988	Binding agent; Coating agent; Cryoprotectant; Diluent; Flavoring agent; Suspending agent; Viscosity-controlling agent
Silicon dioxide	E00670	Not Available	Anticaking agent; Opacifying agent; Viscosity-controlling agent
Talc	E00520	16211421	Anticaking agent; Diluent; Glidant; lubricant
Titanium dioxide	E00322	26042	Coating agent; Colorant; Opacifying agent
Triacetin	E00080	5541	Humectant; Plasticizing agent; Solvent
Vinylpyrrolidone	E00668	Not Available	Binding agent; Coating agent; Disintegrant; Film/membrane-forming agent; Solubilizing agent; Suspending agent
--------------------


⏷ Show the Full List of 26 Pharmaceutical Excipients of This Drug

Pharmaceutical Formulation

Formulation Name	Drug Dosage	Dosage Form	Route
Memantine 5 mg tablet	5 mg	Oral Tablet	Oral
Memantine 10 mg tablet	10 mg	Oral Tablet	Oral
Memantine 14 mg capsule	14 mg	24 HR Extended Release Oral Capsule	Oral

Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4253).
2	Treatment effect size of memantine therapy in Alzheimer disease and vascular dementia. Alzheimer Dis Assoc Disord. 2006 Jul-Sep;20(3):133-7.
3	FDA approval: ado-trastuzumab emtansine for the treatment of patients with HER2-positive metastatic breast cancer. Clin Cancer Res. 2014 Sep 1;20(17):4436-41.
4	BDDCS predictions, self-correcting aspects of BDDCS assignments, BDDCS assignment corrections, and classification for more than 175 additional drugs
5	Critical Evaluation of Human Oral Bioavailability for Pharmaceutical Drugs by Using Various Cheminformatics Approaches
6	An FDA phase I clinical trial of quinacrine sterilization (QS). Int J Gynaecol Obstet. 2003 Oct;83 Suppl 2:S45-9.
7	Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
8	The NMDA receptor antagonist memantine as a symptomatological and neuroprotective treatment for Alzheimer's disease: preclinical evidence. Int J Geriatr Psychiatry. 2003 Sep;18(Suppl 1):S23-32.
9	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
10	Human neurons express the polyspecific cation transporter hOCT2, which translocates monoamine neurotransmitters, amantadine, and memantine. Mol Pharmacol. 1998 Aug;54(2):342-52.
11	Are organic cation transporters capable of transporting prostaglandins? Naunyn Schmiedebergs Arch Pharmacol. 2005 Aug;372(2):125-30.
12	Cisplatin nephrotoxicity is critically mediated via the human organic cation transporter 2. Am J Pathol. 2005 Dec;167(6):1477-84.
13	Relevance of copper transporter 1 and organic cation transporters 1-3 for oxaliplatin uptake and drug resistance in colorectal cancer cells. Metallomics. 2018 Mar 1;10(3):414-425.
14	Cloning and characterization of two human polyspecific organic cation transporters. DNA Cell Biol. 1997 Jul;16(7):871-81.
15	Differential pharmacological in vitro properties of organic cation transporters and regional distribution in rat brain. Neuropharmacology. 2006 Jun;50(8):941-52.
16	Influx Transport of Cationic Drug at the Blood-Retinal Barrier: Impact on the Retinal Delivery of Neuroprotectants. Biol Pharm Bull. 2017;40(8):1139-1145.
17	The organic cation transporters (OCT1, OCT2, EMT) and the plasma membrane monoamine transporter (PMAT) show differential distribution and cyclic expression pattern in human endometrium and early pregnancy decidua. Mol Reprod Dev. 2007 Oct;74(10):1303-11.
18	Metformin is a superior substrate for renal organic cation transporter OCT2 rather than hepatic OCT1. Drug Metab Pharmacokinet. 2005 Oct;20(5):379-86.
19	A species difference in the transport activities of H2 receptor antagonists by rat and human renal organic anion and cation transporters. J Pharmacol Exp Ther. 2005 Oct;315(1):337-45.
20	Altered expression of genes involved in GABAergic transmission and neuromodulation of granule cell activity in the cerebellum of schizophrenia pati... Am J Psychiatry. 2008 Dec;165(12):1594-603.
21	How many modes of action should an antibiotic have Curr Opin Pharmacol. 2008 Oct;8(5):564-73.
22	Amphetamine inhibits the N-methyl-D-aspartate receptor-mediated responses by directly interacting with the receptor/channel complex. J Pharmacol Exp Ther. 2002 Mar;300(3):1008-16.
23	Ketamine modulates theta and gamma oscillations. J Cogn Neurosci. 2010 Jul;22(7):1452-64.
24	Molecular determinants of the anticonvulsant felbamate binding site in the N-methyl-D-aspartate receptor. J Med Chem. 2008 Mar 27;51(6):1534-45.
25	Progress report on new antiepileptic drugs: a summary of the Ninth Eilat Conference (EILAT IX). Epilepsy Res. 2009 Jan;83(1):1-43.
26	Neuroprotective agents for the treatment of acute ischemic stroke. Curr Neurol Neurosci Rep. 2003 Jan;3(1):9-20.
27	Magnesium sulfate diminishes the effects of amide local anesthetics in rat sciatic-nerve block. Reg Anesth Pain Med. 2007 Jul-Aug;32(4):288-95.
28	Emerging drugs for acute ischemic stroke. Expert Opin Emerg Drugs. 2009 Mar;14(1):33-42.
29	Involvement of voltage-gated sodium channels blockade in the analgesic effects of orphenadrine. Pain. 2009 Apr;142(3):225-35.
30	Kulik AV, Wilbur R "Delirium and stereotypy from anticholinergic antiparkinson drugs." Prog Neuropsychopharmacol Biol Psychiatry 6 (1982): 75-82. [PMID: 7202232]
31	Cohen MA, Alfonso CA, Mosquera M. Development of urinary retention during treatment with clozapine and meclizine [published correction appears in Am J Psychiatry 1994 Jun;151(6):952]. Am J Psychiatry. 1994;151(4):619-620. [PMID: 8147469]
32	Cerner Multum, Inc. "UK Summary of Product Characteristics.".